Cases & Deals

Share

GRA Venture Fund invests in Accuitis

May 2018

Client(s) GRA Venture Fund, LLC and GRA Venture Fund (T.E.), LLC

Jones Day represented GRA Venture Fund, LLC and GRA Venture Fund (T.E.), LLC in connection with their purchase of Series A-2 Preferred Stock in a private placement by Accuitis, Inc., a clinical-stage biopharmaceutical company developing multiple first-in-class drug therapies to treat chronic diseases of the skin and eye.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.